All In Biotech

Drug Trial Radar · NCT07483671

Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients

A Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of BPR-101 Capsules in Combination With Metronidazole for the Prevention of Recurrence of Bacterial Vaginosis (BV).

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 15, 2026

Primary completion

Jan 24, 2027

Study completion Jan 24, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial employed a multicenter, randomized, double-blind, parallel, placebo-controlled design to evaluate the preventive effect of BPR-101 capsules combined with metronidazole on the recurrence of BV, as well as the cure rate and safety.

Conditions

  • Bacterial Vaginosis

Interventions

  • BPR-101 capsules:Investigational product for the treatment of BVDrug

    administered vaginally and orally as per study protocol.

  • Placebo:matching the investigational product in appearance, dosage form, and route of administrationOther

    administered vaginally and orally as per study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The recurrence rate of BVTime frame: Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.